Department of Neurological Surgery, University of Washington, Seattle, Washington.
Department of Radiation Oncology, University of Washington, Seattle, Washington.
Neurosurgery. 2019 Aug 1;85(2):E322-E331. doi: 10.1093/neuros/nyy520.
Stereotactic radiosurgery (SRS) is a treatment modality that is frequently used as salvage therapy for small nodular recurrent high-grade gliomas (HGG). Due to the infiltrative nature of HGG, it is unclear if this highly focused technique provides a durable local control benefit.
To determine how demographic or clinical factors influence the pattern of failure following SRS for recurrent high-grade gliomas.
We retrospectively reviewed clinical, radiographic, and follow-up information for 47 consecutive patients receiving SRS for recurrent HGG at our institution between June 2006 and July 2016. All patients initially presented with an HGG (WHO grade III and IV). Following SRS for recurrence, all patients experienced treatment failure, and we evaluated patterns of local, regional, and distant failure in relation to the SRS 50% isodose line.
Most patients with recurrent HGG developed "in-field" treatment failure following SRS (n = 40; 85%). Higher SRS doses were associated with longer time to failure (hazards ratio = 0.80 per 1 Gy increase; 95% confidence interval 0.67-0.96; P = .016). There was a statistically significant increase in distant versus in-field failure among older patients (P = .035). This effect was independent of bevacizumab use (odds ratio = 0.54, P = 1.0).
Based on our experience, the majority of treatment failures after SRS for recurrent HGG were "in-field." Older patients, however, presented with more distant failures. Our results indicate that higher SRS doses delivered to a larger area as fractioned or unfractioned regimen may prolong time to failure, especially in the older population.
立体定向放射外科(SRS)是一种常用于治疗小的结节性复发性高级别神经胶质瘤(HGG)的治疗方式。由于 HGG 的浸润性,尚不清楚这种高度集中的技术是否能提供持久的局部控制益处。
确定人口统计学或临床因素如何影响 SRS 治疗复发性高级别神经胶质瘤后的失败模式。
我们回顾性分析了 2006 年 6 月至 2016 年 7 月在我院接受 SRS 治疗复发性 HGG 的 47 例连续患者的临床、影像学和随访资料。所有患者最初均表现为 HGG(WHO 分级 III 和 IV)。SRS 治疗后复发,所有患者均发生治疗失败,我们评估了与 SRS 50%等剂量线相关的局部、区域和远处失败模式。
大多数复发性 HGG 患者在 SRS 后出现“靶区内”治疗失败(n=40;85%)。较高的 SRS 剂量与失败时间延长相关(风险比=每增加 1 Gy 增加 0.80;95%置信区间 0.67-0.96;P=0.016)。老年患者远处失败的发生率明显高于靶区内失败(P=0.035)。这种效应独立于贝伐单抗的使用(比值比=0.54,P=1.0)。
根据我们的经验,SRS 治疗复发性 HGG 后大多数治疗失败都发生在“靶区内”。然而,老年患者出现更多的远处失败。我们的结果表明,以分割或未分割方案给予更大区域的更高 SRS 剂量可能会延长失败时间,尤其是在老年人群中。